24th May 2016 10:03
LONDON (Alliance News) - GlaxoSmithKline PLC, together with Innoviva Inc, on Tuesday said it saw positive headline results from its study of Relvar Ellipta in chronic obstructive pulmonary disease.
The study, dubbed the Salford Lung Study, showed the treatment achieved a better reduction in exacerbations compared to usual care in patients with chronic obstructive pulmonary disease in an everyday clinical practice setting.
"The Salford Lung Study COPD results support the effectiveness of Relvar. As we move beyond the headline results, we will learn so much more about the medicine and disease management. We believe the results could transform understanding of how patients in everyday clinical practice respond to COPD treatments," said Senior Vice President and Head of Glaxo's Global Respiratory Franchise Eric Dube in a statement.
Analysis remains ongoing, Glaxo said, and a second Salford Lung Study is being conducted in asthma, with results due in 2017.
Shares in Glaxo were up 0.4% at 1,444.00 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline